Trial Profile
A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after excision repair cross-complementation group 1 (ERCC1) protein stratification, in patients with advanced/metastatic non-small cell lung cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jan 2022
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ET Trial
- 20 Jan 2022 Status changed from discontinued to completed.
- 25 Jul 2013 Accrual to date is 50% according to United Kingdom Clinical Research Network record.
- 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.